Literature DB >> 18796127

Sorafenib-induced liver failure.

Christoph Schramm, Gunter Schuch, Ansgar W Lohse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18796127     DOI： 10.1111/j.1572-0241.2008.01982_19.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  12 in total

Review 1.  Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.606

2.  Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.

Authors:  Yongping Yang; Yinying Lu; Chunping Wang; Wenlin Bai; Jianhui Qu; Yan Chen; Xiujuan Chang; Linjing An; Lin Zhou; Zhen Zeng; Min Lou; Jiyun Lv
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

Review 3.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

4.  Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Authors:  Masahide Fukudo; Takuma Ito; Tomoyuki Mizuno; Keiko Shinsako; Etsuro Hatano; Shinji Uemoto; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Hiroshi Seno; Tsutomu Chiba; Kazuo Matsubara
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

5.  Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Authors:  B P Fairfax; S Pratap; I S D Roberts; J Collier; R Kaplan; A M Meade; A W Ritchie; T Eisen; V M Macaulay; A Protheroe
Journal:  BMC Cancer       Date:  2012-12-11       Impact factor: 4.430

6.  Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Yongping Yang; Yinying Lu; Chunping Wang; Wenlin Bai; Jianhui Qu; Yan Chen; Xiujuan Chang; Linjing An; Lin Zhou; Zhen Zeng; Min Lou; Jiyun Lv
Journal:  Cell Biochem Biophys       Date:  2012-06       Impact factor: 2.194

7.  Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.

Authors:  Carl-Henrik Heldin
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-25       Impact factor: 7.285

8.  Sorafenib-induced liver failure: a case report and review of the literature.

Authors:  Anneleen Van Hootegem; Chris Verslype; Werner Van Steenbergen
Journal:  Case Reports Hepatol       Date:  2011-12-12

Review 9.  New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.

Authors:  Kai Qu; Zichao Huang; Ting Lin; Sinan Liu; Hulin Chang; Zhaoyong Yan; Hongxin Zhang; Chang Liu
Journal:  Front Pharmacol       Date:  2016-01-18       Impact factor: 5.810

10.  Organ Atrophy Induced by Sorafenib and Sunitinib - Quantitative Computed Tomography (CT) Evaluation of the Pancreas, Thyroid Gland and Spleen.

Authors:  Hiroaki Takahashi; Katsuhiro Nasu; Manabu Minami; Takahiro Kojima; Hiroyuki Nishiyama; Toshitaka Ishiguro; Takahiro Konishi
Journal:  Pol J Radiol       Date:  2016-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.